PacificHealth Laboratories, Inc. Provides Update on Business
Monday October 15, 9:00 am ET
MATAWAN, N.J.--(BUSINESS WIRE)--PacificHealth Laboratories, Inc. (OTCBB: PHLI - News), a nutrition technology company, provided today an interim third quarter update on their business.
Dr. Robert Portman, President and CEO, said, "Sales results for our sports nutrition products continued to remain strong in the third quarter. We expect to show 20% growth in revenues from the same period in 2006. The growth in our sports nutrition products can be attributed both to the advertising and promotional efforts by Cadbury Schweppes Americas Beverages ("CSAB") in support of Accelerade RTD as well as the continued success our rack, direct internet and other programs have had in expanding distribution and same store sales among sports specialty retailers. The number of total Accelerade servings sold in the third quarter is the highest we have ever seen for this product. This strongly suggests that our audience of users is expanding. While Cadbury Schweppes has publicly announced their disappointment in sales of Accelerade RTD to date, we are encouraged by our own increase in sales and we will continue to work closely with the CSAB sales and marketing team."
Dr. Portman continued, "In the fourth quarter we will initiate a number of marketing and sales efforts for Satiatrim including the launch of radio commercials and ads in Women's World as well as the initiation of a major sampling program to put trial product in the hands of our target audience. We should begin to see the results of these efforts in the fourth quarter."
Dr. Portman added, "At the Obesity Society Annual Scientific Meeting in New Orleans this month, a study will be presented showing the effectiveness of Satiatrim on slowing gastric emptying. I am also extremely excited about some of our latest research results from Hope Hospital in Manchester, England. These results are laying the foundation to allow us to incorporate the Satiatrim technology into new forms and to develop new products that are even more efficacious with a greater duration of action."
